You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSulodexide
Accession NumberDB06271
TypeBiotech
GroupsApproved, Investigational
DescriptionSulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weight6500.0 Da (range 5000-8000)
SequencesNot Available
SynonymsNot Available
External Identifiers
  • KRX-101
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SulonexNot Available
VesselNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII75HGV0062C
CAS number57821-29-1
Pharmacology
IndicationSulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated in the treatment of diabetic kidney disease and diabetic neuropathy. New anti-inflammatory properties have also extended its use in venous disease.
Structured Indications Not Available
PharmacodynamicsThe low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters. Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously. It is capable of inhibiting both anti-IIa and anti-Xa. It promotes fibrinolytic activity by releasing tissue plasminogen activator and reduces plasminogen activator inhibitor. The drug also blocks platelet adhesion and platelet function induced by cathepsin G and thrombin. Research has also shown that Sulodexide had endothelial protective properties by inducing the overexpression of growth factors important for the protection of organs. It has anti-inflammatory properties via its effect on the release of inflammatory mediators from macrophages. This results in anti-proliferative effects such as the regulation of growth factors like VEGF and FGF. The intravenous administration has also been shown capable of releasing tissue factor pathway inhibitor from the endothelium, which also contributes to the anti-thrombotic effects of Sulodexide. Lastly, this drug is known for its ability to inhibit the secretion of MMPs, particularly MMP-9, from leukocytes in a dose dependent manner, resulting in the restoration of the balance with their tissue inhibitors.
Mechanism of actionThrombin inhibition produced by sulodexide is due to the additive effect of its components, namely, heparin cofactor II (HCII) catalysis by dermatan sulfate and antithrombin-III catalysis by fast moving heparin (FMH).
TargetKindPharmacological actionActionsOrganismUniProt ID
Heparin cofactor 2Proteinyes
agonist
HumanP05546 details
Antithrombin-IIIProteinyes
potentiator
HumanP01008 details
Related Articles
AbsorptionSulodexide can be administered via the oral route, IV and IM routes. After oral dosing, the absorption rate being equivalent, the bioavailability is 40-60%. either calculated from the fast-moving heparin fraction or from the dermatan fraction. Bioavailability following IM administration is approximately 90%. After a rapid absorption in the intestine, the dermatan and heparin components start to appear in the plasma. Sulodexide is degraded after ingestion and loses its sulfate groups and both sulfated and unsulfated groups circulate in the blood for up to 24hours. AUC=22.83+/-4.44mg.h/L.
Volume of distribution

Cmax=516+/-77.54ng/mL,
Tmax=1.33+/-0.58h,
Vd=71.24+/-14.06L (b phase).
Sulodexide reaches high concentrations in the plasma and is widely distributed in the endothelial layer. Binding to endothelial cell receptors in arteries and veins contributes to its rapid distribution profile.

Protein bindingNot Available
Metabolism

It is mainly metabolized in the liver.

Route of eliminationSulodexide is eliminated via the renal, fecal and bile routes. The main clearance occurs renally and accounts for elimination of 55+2.9% of the drug over 96 hours. The fecal and bile routes remove the rest of the drug over 48 hours, which accounts for 23.5+/-2.5% for both routes.
Half lifeThe elimination half-life was 11.7 +/- 2.0 h after intravenous administration, 18.7 +/- 4.1 h after 50 mg per os, and 25.8 +/- 1.9 h after 100 mg per os.
Clearance

2.70+/-0.58L/h

ToxicitySulodexide seems to be well tolerated. Most adverse effects reported are related to the GI system and seem to be transient in nature. Among others adverse reactions are diarrhea, epigastralgia, dyspepsia, heartburn and dizziness. Allergic reactions, such as skin rash, have also been reported but are very rare.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabAbciximab may increase the anticoagulant activities of Sulodexide.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Sulodexide.Approved
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Sulodexide.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Sulodexide.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Sulodexide.Approved
AllylestrenolThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Allylestrenol.Approved
AlprostadilAlprostadil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Sulodexide.Approved
AltrenogestThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Sulodexide.Investigational
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Sulodexide.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Sulodexide.Approved
AncrodAncrod may increase the anticoagulant activities of Sulodexide.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Sulodexide.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Sulodexide.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Sulodexide.Approved
Antithrombin III humanSulodexide may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Sulodexide.Approved
ApremilastApremilast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
AprotininThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Sulodexide.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Aripiprazole.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Asenapine.Approved
AstaxanthinAstaxanthin may increase the anticoagulant activities of Sulodexide.Investigational
AtazanavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Atazanavir.Approved, Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Sulodexide.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Sulodexide.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Sulodexide.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Sulodexide.Approved
BendroflumethiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Bendroflumethiazide.Approved
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Sulodexide.Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Sulodexide.Investigational
BetamethasoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Sulodexide.Investigational
BivalirudinBivalirudin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Brexpiprazole.Approved
BromfenacBromfenac may increase the anticoagulant activities of Sulodexide.Approved
BucillamineBucillamine may increase the anticoagulant activities of Sulodexide.Investigational
BumetanideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Bumetanide.Approved
BuserelinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Buserelin.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Sulodexide.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Sulodexide.Approved
CarprofenCarprofen may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Sulodexide.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
CeritinibThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ceritinib.Approved
CertoparinSulodexide may increase the anticoagulant activities of Certoparin.Approved
ChloroquineChloroquine may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Sulodexide.Withdrawn
ChlorpropamideSulodexide may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorthalidone.Approved
CilostazolCilostazol may increase the anticoagulant activities of Sulodexide.Approved
Citric AcidCitric Acid may increase the anticoagulant activities of Sulodexide.Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Sulodexide.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Sulodexide.Approved, Nutraceutical
ClozapineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Clozapine.Approved
CollagenaseThe risk or severity of adverse effects can be increased when Sulodexide is combined with Collagenase.Approved
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Sulodexide.Approved
CorticotropinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Cortisone acetate.Approved
CurcuminCurcumin may increase the anticoagulant activities of Sulodexide.Investigational
Cyproterone acetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Sulodexide.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Sulodexide.Approved
DabrafenibThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dabrafenib.Approved
DalteparinSulodexide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSulodexide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DanazolThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Danazol.Approved
DarunavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Sulodexide is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Sulodexide is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Sulodexide.Investigational
DesirudinSulodexide may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Sulodexide.Investigational
DesogestrelThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DextranSulodexide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Sulodexide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Sulodexide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Sulodexide may increase the anticoagulant activities of Dextran 75.Approved
DiazoxideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Diazoxide.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Sulodexide.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Sulodexide.Approved
DienogestThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Sulodexide.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Sulodexide.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Sulodexide.Approved
DisopyramideSulodexide may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleDitazole may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Sulodexide.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Sulodexide.Investigational
DydrogesteroneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
E6201E6201 may increase the anticoagulant activities of Sulodexide.Investigational
EbselenEbselen may increase the anticoagulant activities of Sulodexide.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Sulodexide.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Sulodexide.Approved
EpinastineEpinastine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
EpinephrineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may increase the anticoagulant activities of Sulodexide.Approved
eplivanserineeplivanserine may increase the anticoagulant activities of Sulodexide.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Sulodexide.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Sulodexide.Approved, Vet Approved
EstroneEstrone may decrease the anticoagulant activities of Sulodexide.Approved
Estrone sulfateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Etacrynic acid.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Sulodexide.Approved, Investigational
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Sulodexide.Approved
Ethyl biscoumacetateSulodexide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Sulodexide.Approved
EtonogestrelThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Sulodexide.Approved
EverolimusThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Everolimus.Approved
exisulindexisulind may increase the anticoagulant activities of Sulodexide.Investigational
FenbufenFenbufen may increase the anticoagulant activities of Sulodexide.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Sulodexide.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Sulodexide.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
FludrocortisoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Fludrocortisone.Approved
FluindioneSulodexide may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Sulodexide.Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
FondaparinuxSulodexide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Sulodexide.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Fosamprenavir.Approved
FurosemideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Furosemide.Approved, Vet Approved
GabexateSulodexide may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Sulodexide.Investigational
GestodeneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Gestrinone.Approved
GliclazideSulodexide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSulodexide may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSulodexide may increase the hypoglycemic activities of Glipizide.Approved
GlyburideSulodexide may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Goserelin.Approved
HeminHemin may increase the anticoagulant activities of Sulodexide.Approved
HeparinHeparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Sulodexide.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Sulodexide.Investigational
HirulogHirulog may increase the anticoagulant activities of Sulodexide.Experimental
HistrelinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Histrelin.Approved
HMPL-004HMPL-004 may increase the anticoagulant activities of Sulodexide.Investigational
HydrochlorothiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sulodexide.Approved
IbudilastIbudilast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Sulodexide.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Sulodexide.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Sulodexide.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Sulodexide.Approved, Nutraceutical
idraparinuxSulodexide may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
IloperidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Iloperidone.Approved
IloprostIloprost may increase the anticoagulant activities of Sulodexide.Approved, Investigational
IndapamideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Indapamide.Approved
IndinavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Sulodexide.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Sulodexide.Withdrawn
Insulin AspartSulodexide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSulodexide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSulodexide may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSulodexide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSulodexide may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSulodexide may increase the hypoglycemic activities of Insulin Lispro.Approved
IsoxicamIsoxicam may increase the anticoagulant activities of Sulodexide.Withdrawn
Kct 0809Kct 0809 may increase the anticoagulant activities of Sulodexide.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Sulodexide.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Sulodexide.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Sulodexide.Approved
LanreotideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lanreotide.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Sulodexide.Approved
LeuprolideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Sulodexide.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Sulodexide.Approved, Nutraceutical
LisofyllineLisofylline may increase the anticoagulant activities of Sulodexide.Investigational
LopinavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lopinavir.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Sulodexide.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Sulodexide.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
LurasidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lurasidone.Approved
LynestrenolThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Sulodexide.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Sulodexide.Approved
MecaserminSulodexide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Sulodexide.Approved
Megestrol acetateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Sulodexide.Approved
MestranolMestranol may decrease the anticoagulant activities of Sulodexide.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Sulodexide.Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Sulodexide.Experimental
MethotrimeprazineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methyclothiazide.Approved
MethylprednisoloneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetolazoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Metolazone.Approved
MifepristoneSulodexide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Sulodexide.Approved
MizoribineMizoribine may increase the anticoagulant activities of Sulodexide.Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Sulodexide.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Sulodexide.Approved
NadroparinSulodexide may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Sulodexide.Investigational
NaftifineNaftifine may increase the anticoagulant activities of Sulodexide.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Sulodexide.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
NateglinideSulodexide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 4016NCX 4016 may increase the anticoagulant activities of Sulodexide.Investigational
NelfinavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Nelfinavir.Approved
NepafenacNepafenac may increase the anticoagulant activities of Sulodexide.Approved
NiacinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Sulodexide.Approved
NilotinibThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Sulodexide is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Sulodexide.Investigational
NomegestrolThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Norethisterone.Approved
NorgestimateThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Norgestimate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Sulodexide is combined with Obinutuzumab.Approved
OctreotideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Olanzapine.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Sulodexide.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Sulodexide.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Sulodexide is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Sulodexide.Approved
OrgoteinOrgotein may increase the anticoagulant activities of Sulodexide.Vet Approved
OtamixabanSulodexide may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Sulodexide.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Sulodexide.Withdrawn
PaliperidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Paliperidone.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Sulodexide.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Sulodexide.Approved
PasireotideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pasireotide.Approved
PentamidineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pentamidine.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Sulodexide.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Sulodexide.Approved
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Sulodexide.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PiperazineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pipotiazine.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Sulodexide.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Sulodexide.Investigational
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Sulodexide.Approved
PolythiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Polythiazide.Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Sulodexide.Approved
PrednisoloneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Prednisone.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Sulodexide.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Sulodexide.Approved
Protein CSulodexide may increase the anticoagulant activities of Protein C.Approved
Protein S humanSulodexide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSulodexide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Sulodexide.Investigational
QuetiapineThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quetiapine.Approved
QuinestrolQuinestrol may decrease the anticoagulant activities of Sulodexide.Approved
QuinethazoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quinethazone.Approved
QuinineSulodexide may increase the hypoglycemic activities of Quinine.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Sulodexide.Investigational
RepaglinideSulodexide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Sulodexide.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Sulodexide.Approved
ReviparinSulodexide may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Sulodexide.Approved
RisperidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ritonavir.Approved, Investigational
RivaroxabanSulodexide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Sulodexide.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
S EquolS Equol may decrease the anticoagulant activities of Sulodexide.Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Sulodexide.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Sulodexide.Approved
SaquinavirThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Saquinavir.Approved, Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Sulodexide.Investigational
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Sulodexide.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Sulodexide.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Sulodexide.Approved, Vet Approved
SirolimusThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Sirolimus.Approved, Investigational
SRT501SRT501 may increase the anticoagulant activities of Sulodexide.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Sulodexide.Approved
SugammadexSugammadex may increase the anticoagulant activities of Sulodexide.Approved
SulfadiazineSulodexide may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulodexide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Sulodexide.Approved
SulfisoxazoleSulodexide may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Sulodexide.Approved
SunitinibSulodexide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Sulodexide.Approved, Withdrawn
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Sulodexide.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Sulodexide.Approved
TacrolimusThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Tacrolimus.Approved, Investigational
TemsirolimusThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Sulodexide.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Sulodexide.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Sulodexide.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Sulodexide.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Sulodexide.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Sulodexide.Approved
TiboloneTibolone may increase the anticoagulant activities of Sulodexide.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Sulodexide.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Sulodexide.Approved
TinoridineTinoridine may increase the anticoagulant activities of Sulodexide.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Sulodexide.Approved
TipranavirTipranavir may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Sulodexide.Approved
TolazamideSulodexide may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideSulodexide may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Sulodexide.Approved
TolmetinTolmetin may increase the anticoagulant activities of Sulodexide.Approved
TorasemideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Sulodexide is combined with Tositumomab.Approved
TranilastTranilast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Sulodexide.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Sulodexide.Approved
TriptorelinThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Sulodexide.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Sulodexide.Investigational, Withdrawn
Vitamin EVitamin E may increase the anticoagulant activities of Sulodexide.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Sulodexide.Approved
VorinostatThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinWarfarin may increase the anticoagulant activities of Sulodexide.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
Ym150Sulodexide may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Sulodexide.Approved
ZeranolZeranol may decrease the anticoagulant activities of Sulodexide.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Sulodexide.Approved, Investigational, Withdrawn
ZiprasidoneThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ziprasidone.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Sulodexide.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S: Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003 Mar 15;109(5-6):333-9. [PubMed:12818259 ]
  2. Harenberg J: Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20. [PubMed:9436179 ]
  3. Lasierra-Cirujeda J, Coronel P, Aza M, Gimeno M: Use of sulodexide in patients with peripheral vascular disease. J Blood Med. 2010;1:105-15. doi: 10.2147/JBM.S10558. Epub 2010 Jun 15. [PubMed:22282689 ]
  4. Hoppensteadt DA, Fareed J: Pharmacological profile of sulodexide. Int Angiol. 2014 Jun;33(3):229-35. [PubMed:24936531 ]
External Links
ATC CodesB01AB11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner.Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.
Gene Name:
SERPIND1
Uniprot ID:
P05546
Molecular Weight:
57070.16 Da
References
  1. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S: Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003 Mar 15;109(5-6):333-9. [PubMed:12818259 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
Gene Name:
SERPINC1
Uniprot ID:
P01008
Molecular Weight:
52601.935 Da
References
  1. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S: Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003 Mar 15;109(5-6):333-9. [PubMed:12818259 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Harenberg J: Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20. [PubMed:9436179 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:20 / Updated on August 17, 2016 12:24